Reviva Pharmaceuticals Hldg Inc (RVPH)

Jan 7, 2025, 8:00 AM EST - 10 days ago

Reviva to Participate in the Lytham Partners 2025 Investor Healthcare Summit

Dec 16, 2024, 5:18 PM EST - 4 weeks ago

Reviva Announces Proposed Public Offering

Dec 11, 2024, 3:37 PM EST - 5 weeks ago

Reviva Pharmaceuticals: Upcoming Events May Generate Excitement, But Cash Is Low

Nov 14, 2024, 5:25 PM EST - 2 months ago

Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 6, 2024, 8:00 AM EST - 2 months ago

Reviva to Present Positive Speech Latency Data for Brilaroxazine in Schizophrenia From the Phase 3 RECOVER Trial at the CNS Summit 2024

Oct 31, 2024, 8:00 AM EDT - 2 months ago

Reviva to Participate in the UBS Global Healthcare Conference

Oct 8, 2024, 8:00 AM EDT - 3 months ago

Reviva to Participate in the 2024 Maxim Healthcare Virtual Summit

Oct 2, 2024, 8:30 AM EDT - 3 months ago

Reviva to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Aug 21, 2024, 6:00 AM EDT - 5 months ago

Reviva Pharmaceuticals Announces Pricing of $5.0 Million Underwritten Offering Priced At-the-Market Under Nasdaq Rules

Jul 9, 2024, 8:00 AM EDT - 6 months ago

Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Hypertension

May 29, 2024, 4:45 PM EDT - 8 months ago

Reviva Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

May 28, 2024, 8:00 AM EDT - 8 months ago

Reviva Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

May 21, 2024, 8:00 AM EDT - 8 months ago

Reviva to Participate in the BIO International Convention

May 15, 2024, 8:00 AM EDT - 8 months ago

Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

May 14, 2024, 8:00 AM EDT - 8 months ago

Reviva Reports First Quarter 2024 Financial Results and Recent Business Highlights

May 13, 2024, 8:00 AM EDT - 8 months ago

Reviva to Present New Preclinical Efficacy Data on Brilaroxazine in Idiopathic Pulmonary Fibrosis at 2024 ATS International Conference

May 9, 2024, 8:00 AM EDT - 9 months ago

Reviva to Present New Non-Clinical Pharmacology Data on Brilaroxazine at the ASPET 2024 Annual Meeting

Apr 15, 2024, 8:30 AM EDT - 9 months ago

Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia

Apr 15, 2024, 8:05 AM EDT - 9 months ago

Reviva Reports Full Year 2023 Financial Results and Recent Business Highlights

Mar 28, 2024, 8:00 AM EDT - 10 months ago

Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the SIRS 2024 Annual Meeting

Mar 26, 2024, 8:00 AM EDT - 10 months ago

Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the ASCPT 2024 Annual Meeting

Mar 11, 2024, 8:00 AM EDT - 11 months ago

Reviva to Present at the UBS Virtual CNS Day

Mar 7, 2024, 8:00 AM EST - 11 months ago

Reviva to Present at the 36th Annual ROTH Conference

Feb 20, 2024, 8:00 AM EST - 11 months ago

Reviva Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference

Feb 6, 2024, 8:00 AM EST - 1 year ago

Reviva to Host KOL Event to Discuss Topline Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia

Jan 25, 2024, 8:00 AM EST - 1 year ago

Reviva Pharmaceuticals to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference

Jan 10, 2024, 8:00 AM EST - 1 year ago

Reviva to Present at Webull LIVE! Healthcare Webinar on January 17

Jan 4, 2024, 8:00 AM EST - 1 year ago

Reviva Provides Corporate and Program Updates and Highlights Key Upcoming Milestones

Dec 11, 2023, 8:00 AM EST - 1 year ago

Reviva to Participate in the Zacks Small-Cap Research Life Sciences Investor Forum

Nov 30, 2023, 4:05 PM EST - 1 year ago

Reviva Pharmaceuticals to Participate in The Benchmark Company's Upcoming Discovery One-on-One Investor Conference

Nov 20, 2023, 4:05 PM EST - 1 year ago

Reviva Announces Closing of $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Nov 16, 2023, 8:00 AM EST - 1 year ago

Reviva Announces $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Nov 14, 2023, 4:01 PM EST - 1 year ago

Reviva Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Nov 2, 2023, 3:11 AM EDT - 1 year ago

Reviva Pharmaceuticals: Positive Results In Phase 3 But The Stock Is Back Where It Started

Oct 30, 2023, 7:41 AM EDT - 1 year ago

Reviva Pharma's schizophrenia drug succeeds in late-stage study

Oct 30, 2023, 7:30 AM EDT - 1 year ago

Reviva Announces Positive Topline Results from Global Pivotal Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia

Sep 29, 2023, 9:00 AM EDT - 1 year ago

Sharps Technology, Reviva Pharmaceuticals, and American Resources Corp. Interviews to Air on the RedChip Money Report(R) on Bloomberg TV

AREC STSS

Sep 27, 2023, 2:48 AM EDT - 1 year ago

Reviva Pharmaceuticals: A Binary Event Approaches With Results From RECOVER

Sep 25, 2023, 6:00 AM EDT - 1 year ago

Reviva Announces Last Patient Evaluated in Pivotal Phase 3 RECOVER Trial for Brilaroxazine in Schizophrenia

Sep 22, 2023, 1:30 PM EDT - 1 year ago

Reviva Pharmaceuticals Holdings, Inc. and Aridis Pharmaceuticals, Inc. Interviews to Air on the RedChip Money Report(R) on Bloomberg TV

Sep 7, 2023, 6:00 AM EDT - 1 year ago

Reviva to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

Aug 17, 2023, 6:00 AM EDT - 1 year ago

Reviva Announces Enrollment Completion for Pivotal Phase 3 RECOVER Study for Brilaroxazine in Schizophrenia

Aug 14, 2023, 4:01 PM EDT - 1 year ago

Reviva Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Aug 2, 2023, 12:45 PM EDT - 1 year ago

RedChip Launches 'Small Stocks, Big Money' Podcast

BFRG LTRN STSS ZOM

Jul 31, 2023, 8:00 AM EDT - 1 year ago

Reviva Pharmaceuticals to Present at Upcoming Investor Conferences in August

Jun 26, 2023, 6:00 AM EDT - 1 year ago

Reviva Pharmaceuticals to be Added to Russell Microcap® Index

Jun 22, 2023, 6:00 AM EDT - 1 year ago

Reviva Pharmaceuticals Announces 80% Global Enrollment Update for Pivotal Phase 3 RECOVER Study Evaluating Brilaroxazine for Schizophrenia

Jun 15, 2023, 6:00 AM EDT - 1 year ago

Reviva Pharmaceuticals to Present at Upcoming Investor Conferences in June